Abstract
Leukocyte-function associated antigen-1 (LFA-1) is an αLβ2 chain integrin expressed on the surface of endothelial cells that modulates the behavior of leukocytes by mediating their adhesion to other cells through its interaction to cell-surface ligands. The most important ligand of LFA-1 is ICAM-1 which is expressed on the surface of endothelial cells. The interaction between LFA-1 and ICAM-1 is involved in inflammatory responses and is therefore implicated in inflammatory pathologies and autoimmune diseases; and, in addition, it is involved in many cancer processes. In light of this, there is great interest in developing small molecule, orally available, inhibitors of the LFA-1/ICAM-1 interaction. A structurally diverse collection of small molecule inhibitors has been characterized and developed either to bind the IDAS site of the αL I-domain or to the MIDAS of the β2 I-like domain. In this review, a summary of the structure and regulation of LFA-1 will be given, followed by a description of the different classes of inhibitors that have been described to date.
Keywords: LFA-1, ICAM-1, integrin, cell adhesion, inhibitors, allosteric inhibitors, protein-protein interaction
Current Pharmaceutical Design
Title: Inhibitors Targeting the LFA-1/ICAM-1 Cell-Adhesion Interaction: Design and Mechanism of Action
Volume: 14 Issue: 22
Author(s): Tahl Zimmerman and Francisco J. Blanco
Affiliation:
Keywords: LFA-1, ICAM-1, integrin, cell adhesion, inhibitors, allosteric inhibitors, protein-protein interaction
Abstract: Leukocyte-function associated antigen-1 (LFA-1) is an αLβ2 chain integrin expressed on the surface of endothelial cells that modulates the behavior of leukocytes by mediating their adhesion to other cells through its interaction to cell-surface ligands. The most important ligand of LFA-1 is ICAM-1 which is expressed on the surface of endothelial cells. The interaction between LFA-1 and ICAM-1 is involved in inflammatory responses and is therefore implicated in inflammatory pathologies and autoimmune diseases; and, in addition, it is involved in many cancer processes. In light of this, there is great interest in developing small molecule, orally available, inhibitors of the LFA-1/ICAM-1 interaction. A structurally diverse collection of small molecule inhibitors has been characterized and developed either to bind the IDAS site of the αL I-domain or to the MIDAS of the β2 I-like domain. In this review, a summary of the structure and regulation of LFA-1 will be given, followed by a description of the different classes of inhibitors that have been described to date.
Export Options
About this article
Cite this article as:
Zimmerman Tahl and Blanco J. Francisco, Inhibitors Targeting the LFA-1/ICAM-1 Cell-Adhesion Interaction: Design and Mechanism of Action, Current Pharmaceutical Design 2008; 14 (22) . https://dx.doi.org/10.2174/138161208785740225
DOI https://dx.doi.org/10.2174/138161208785740225 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Current Pharmaceutical Design Role of C1858T Polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian Children and Adolescents with Type 1 Diabetes
Current Diabetes Reviews Neurological Involvement as the Initial Manifestation in Primary Sjögren's Syndrome - A Case Report
Current Rheumatology Reviews Systemic Immunomodulation of Autoimmune Disease Using MHC-Derived Recombinant TCR Ligands
Current Drug Targets - Inflammation & Allergy Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews Altered Peptide Ligand Antagonism: From Immune Evasion to Immunotherapy
Drug Design Reviews - Online (Discontinued) Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of Synbiotics for Ulcerative Colitis Treatment
Current Clinical Pharmacology Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Synthesis and Evaluation of Cytotoxicity and Inhibitory Effect on Nitric Oxide Production by J774A.1 Macrophages of New Anthraquinone Derivatives
Medicinal Chemistry Possible Role of DNA Methylation in the Induction of Systemic Lupus Erythematosus
Current Rheumatology Reviews Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy Editorial (Thematic Issues: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis)
Current Drug Targets Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design